Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29899081 | 1.00 | HCAR2 (0.33) | HCAR2 | |
| SCHEMBL28574020 | 0.79 | GPR119 (0.36) | — | |
| SCHEMBL5314333 | 0.74 | KDM4E (0.33) | — | |
| SCHEMBL7470130 | 0.73 | — | — | |
| SCHEMBL28471542 | 0.72 | — | — | |
| SCHEMBL12497518 | 0.71 | PDE3B (0.33) | HCAR2 | |
| SCHEMBL1721216 | 0.68 | HDAC1 (0.46) | HCAR2 | |
| SCHEMBL29379757 | 0.68 | HDAC1 (0.46) | HCAR2 | |
| SCHEMBL19031125 | 0.67 | KDM4E (0.34) | — | |
| SCHEMBL3670803 | 0.67 | HCAR2 (0.31) | HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107349-A1 | HETEROCYCLIC INHIBITORS OF CYCLIN-DEPENDENT KINASES | ANTARES THERAPEUTICS, INC. (US) | 2026-05-21 | — | — | WO | disclosed |
| US-20250388593-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2025-12-25 | — | — | US | disclosed |
| EP-3880208-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2024-11-20 | — | — | EP | disclosed |
| CN-118184657-A | PARP7 inhibitor and preparation method and application thereof | 成都先导药物开发股份有限公司 | 2024-06-14 | — | — | CN | disclosed |
| EP-3852533-B1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO INC (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20230279000-A1 | PYRIDOPYRIMIDINE DERIVATIVES USEFUL IN MODULATION OF AHR SIGNALLING | JAGUAHR THERAPEUTICS PTE LTD (SG) | 2023-09-07 | — | — | US | disclosed |
| EP-3710439-B1 | KRAS G12C INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2023-02-15 | — | — | EP | disclosed |
| CN-115244048-A | Pyridopyrimidine derivatives useful for modulating AhR signaling | 捷豹治疗有限公司 | 2022-10-25 | — | — | CN | disclosed |
| EP-4010333-A1 | PLASMA KALLIKREIN INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2022-06-15 | — | — | EP | disclosed |
| EP-3941475-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | Goldfinch Bio, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| CN-113939295-A | Pyridazinones and methods of use thereof | 金翅雀生物公司 | 2022-01-14 | — | — | CN | disclosed |
| EP-3852533-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | Goldfinch Bio, Inc. (US) | 2021-07-28 | — | — | EP | disclosed |
| CN-112911935-A | Pyridazinones and methods of use thereof | 金翅雀生物公司 | 2021-06-04 | — | — | CN | disclosed |
| WO-2020191056-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| EP-3710439-A1 | KRAS G12C INHIBITORS | Mirati Therapeutics, Inc. (US) | 2020-09-23 | — | — | EP | disclosed |
| WO-2020061162-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230279000-A1 | PYRIDOPYRIMIDINE DERIVATIVES USEFUL IN MODULATION OF AHR SIGNALLING | AHR, ARNT, PAH | HCAR2 66/4885 |
| US-20250388593-A1 | CEREBLON E3 LIGASE BINDING COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND PRODUCTION METHOD THEREFOR | CRBN, CUL1, CBL | HCAR2 3159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.